

16<sup>th</sup> October, 2023

**BSE Limited**  
P.J. Towers, Dalal Street, Fort,  
Mumbai- 400 001  
BSE scrip code: 543635

**National Stock Exchange of India Limited**  
Exchange Plaza, Bandra-Kurla Complex,  
Bandra (East), Mumbai – 400 051  
NSE symbol: PPLPHARMA

**Sub: Intimation of a Press Release regarding In-Vitro Biology Capabilities at the Ahmedabad Discovery Services Site of the Company**

Dear Sir / Madam,

This is further to the press release dated 4<sup>th</sup> January, 2022 (*prior to listing of the Company*) whereby the Company's Pharma Solutions (PPS) business had announced an investment in a high-throughput screening facility that would augment the existing in-vitro biology capabilities at its drug discovery services site in Ahmedabad, India.

We now wish to inform that the Company is announcing the launch of the said high-throughput screening facility and a Press Release in that regard is attached for your ready reference.

Thanking you,

Yours truly,  
For **Piramal Pharma Limited**

**Tanya Sanish**  
Company Secretary

Encl: a/a

## PRESS RELEASE

### **Piramal Pharma Solutions Launches In-Vitro Biology Capabilities at Ahmedabad Discovery Services Site**

- Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
- Expansion couples new biology services with existing chemistry capabilities
- Brings added value to customers by providing an integrated set of discovery capabilities to the market

**Mumbai, India | October 16, 2023:** Piramal Pharma Limited's Pharma Solutions (PPS) business, a leading Contract Development and Manufacturing Organization (CDMO), today formally announced the launch of a world-class high-throughput screening facility that augments the existing in-vitro biology capabilities at its drug discovery services site in Ahmedabad, India. This new expansion significantly adds primary and secondary screening capabilities of compounds prepared at the Ahmedabad site.

With this expansion, Piramal Pharma Solutions is uniquely positioned to provide clients with an integrated set of discovery capabilities and leverage a wide range of in-vitro screening technology tools to support its broad portfolio of research services. The goal is to generate data that provides a superior data package for clients and enhance the company's value as an outsourcing partner. The benefits of this new investment will be seen in an improved experience for PPS discovery services customers. The integration of chemistry and biology services under one roof promises to add high efficiency to the discovery process. To enable this expansion, PPS is committed to bringing in experienced personnel with a demonstrated track record in biology services, complementing the existing technical and operational expertise.



Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions said, "Through these enhanced in-vitro biology services, our drug discovery team will be able to provide clients with decision-driving information earlier and will be an even more effective partner in the drug discovery process."

The new high-throughput screening format enables PPS to evaluate and screen large collections using various assay platform technologies including, but not limited to, TR-FRET (Time-Resolved Fluorescence Resonance Energy Transfer) / HTRF (Homogeneous Time-Resolved Fluorescence), Fluorescence Polarization (FP), absorbance, Luminescence/Electrochemiluminescence (ECL), AlphaScreen, LanthaScreen, flow cytometry and high-content imaging.

These platforms will be applicable to a variety of targets including but not limited to G-Protein-Coupled Receptors (GPCRs) and kinases.

\*\*\*



ImageXpress Confocal Microscope HT.ai (Molecular Devices)



Echo 650 (Acoustic Dispensing) and LSR Fortessa X20 (BD)



FLIPR Penta (Molecular Devices)



Biomek i7 (Beckman Coulter)

### About Piramal Pharma Solutions

Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This

enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited.

For more information visit: [www.piramalpharmasolutions.com](http://www.piramalpharmasolutions.com) | [LinkedIn](#) | [Facebook](#) | [Twitter](#)

### **About Piramal Pharma Limited**

Piramal Pharma Limited (PPL, NSE: PPLPHARMA | BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the-counter products. In addition, one of PPL's associate companies, Allergan India Private Limited is a JV with AbbVie Inc. and has emerged as one of the market leaders in the ophthalmology therapy area. In October 2020, PPL received a 20% strategic growth investment from the Carlyle Group.

For more information visit: [www.piramal.com/pharma](http://www.piramal.com/pharma) | [LinkedIn](#) | [Facebook](#) | [Twitter](#)

---

#### **For Media Queries:**

Rajiv Banerjee  
Group Head - Corporate Communications  
[rajiv.banerjee@piramal.com](mailto:rajiv.banerjee@piramal.com)

#### **For Investors:**

Gagan Borana  
General Manager - Investor Relations & Sustainability  
[gagan.borana@piramal.com](mailto:gagan.borana@piramal.com)

---